Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM-Reference-Cited by-同舟云学术

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

Published:2014-12-15 Issue:3 Volume:22 Page:570-577
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Voloshyna N.¹,Havrdová E.²,Hutchinson M.³,Nehrych T.⁴,You X.⁵,Belachew S.⁵,Hotermans C.⁵,Paes D.⁵

Affiliation:

1. Institute of Neurology, Psychiatry and Narcology NAMS of Ukraine Kharkiv Ukraine

2. First Faculty of Medicine Charles University Prague Czech Republic

3. St Vincent's Hospital Dublin Ireland

4. Lviv Regional Clinical Hospital Lviv National Medical University Lviv Ukraine

5. Biogen Idec Inc. Cambridge MA USA

Funder

Biogen Idec

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.12618

Reference21 articles.

1. Impact of mobility impairment in multiple sclerosis 2 − patients' perspectives;Asch P;Eur Neurol Rev,2011

2. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable

3. Social and economic burden of walking and mobility problems in multiple sclerosis

4. Impact of Walking Impairment in Multiple Sclerosis

5. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab;Journal of Clinical Medicine;2023-12-19

2. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-04

3. Fifteen-year experience with natalizumab in the treatment of multiple sclerosis-a description of 15 clinical cases;AKTUAL NEUROL;2022

4. Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies;PharmacoEconomics;2020-09-29

5. Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?;Journal of Neural Transmission;2019-05-16